The month ahead: September’s upcoming events
It’s back to school for biotech, with a packed conference schedule.
It’s back to school for biotech, with a packed conference schedule.
Second time lucky for Zynyz, Amgen’s PRMT5 comeback, and other possible surprises.
Five years after AbbVie pulled the plug on rova-T, DLL3 comes under the spotlight again.
While Roche, Lilly and Merck push on aggressively, Novartis throws in the towel.
The group reaffirms pancreatic cancer promise with RMC-6236, but has it found the best dose?
Micromet’s tech has yielded two marketed drugs, one still in the clinic... and 14 discontinuations.
Meanwhile, Torl BioTherapeutics appears to be catching up with BioNTech.